Fibralign Begins European Trial of Surgical Mesh for Preventing Secondary Lymphedema
Union City, Calif.-based Fibralign announced that it has enrolled the first patient in a European clinical trial evaluating its BioBridge Collagen Matrix as a preventative treatment for secondary lymphedema.
Lymphedema, or swelling in an arm or leg, is most commonly caused by the removal or damage of lymph nodes during cancer treatment. The study aims to enroll 40 patients with advanced- stage breast cancer who require axillary lymph-node dissection, a surgical intervention that involves removing compromised lymph nodes to reduce the spread of cancer.
The biodegradable surgical mesh recently earned CE mark certification for use in supporting lymphatic-tissue repair.